Systematic review of 58 CBD trials found it works for anxiety but has inconsistent results for other conditions

Q: Does CBD work for anxiety?

The evidence is most consistent for anxiety. Across multiple trials, CBD appeared to have anxiolytic (anxiety-reducing) properties. For other conditions, results were inconsistent.

Q: Why are results so inconsistent for other conditions?

Most studies had very small samples (under 40 participants), used widely varying doses (400 mcg to 6,000 mg), and tested different CBD products. This variability makes it difficult to draw clear conclusions.

Q: Is CBD safe?

In the studies reviewed, CBD was generally safe and well-tolerated, even at high doses. However, the authors note that clearer dosing guidelines and increased regulation of CBD products are needed.

A systematic review of 58 randomized trials found CBD appears to be anxiolytic, but its effectiveness for other non-seizure conditions including psychosis, schizophrenia, and substance use disorders was highly variable.

Tang, Yuni et al.·Pharmaceutical medicine·2022·Strong EvidenceSystematic Review

CBD (1125)Medical Cannabis (1546)Anxiety (227)

Quick Facts

Study Type

Systematic Review

Evidence

Strong Evidence

Sample

N=40

What This Study Found

CBD appears to be anxiolytic (anxiety-reducing). Its effectiveness for other conditions was highly variable. Mental health was the most studied topic (53% of trials). 72% of studies had fewer than 40 participants. Doses ranged from 400 micrograms to 6,000 mg. CBD was generally safe and well-tolerated even at high doses.

Key Numbers

58 RCTs from 8 countries. 47% conducted in healthy populations. 14% restricted to males. 72% had fewer than 40 participants. Doses ranged 400 mcg to 6,000 mg. 53% studied mental health outcomes. Anxiety showed most consistent positive results.

How They Did This

Systematic review of 58 randomized clinical trials from seven databases across eight countries. Excluded seizure-related studies. Included only trials using CBD derived from Cannabis sativa with <3% THC. Independent dual reviewing and risk of bias assessment.

Why This Research Matters

As CBD products flood the market with claims for dozens of conditions, this comprehensive review clarifies that only for anxiety does the evidence consistently support effectiveness, while most other claims lack reliable evidence.

The Bigger Picture

The huge gap between market claims for CBD and the actual clinical trial evidence is starkly illustrated by this review. Larger, more rigorous trials are urgently needed for most proposed indications.

What This Study Doesn't Tell Us

Most included trials were small (72% had fewer than 40 participants). The wide range of doses and formulations makes cross-study comparison difficult. Some conditions had very few trials.

Questions This Raises

?Why does CBD work more consistently for anxiety than other conditions?
?What is the optimal dose for anxiolytic effects?
?Would standardized CBD products perform better in trials than the heterogeneous products tested?

Trust & Context

Key Stat:: Anxiety was the only condition with consistent positive CBD results
Evidence Grade:: Strong: comprehensive systematic review of 58 RCTs with rigorous methodology and dual reviewing.
Study Age:: Published in 2022.
Original Title:: The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.
Published In:: Pharmaceutical medicine, 36(6), 353-385 (2022)
Authors:: Tang, Yuni, Tonkovich, Kolbi L, Rudisill, Toni Marie
Database ID:: RTHC-04256

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer

This study

Randomized Controlled Trial

Cohort / Case-Control

Cross-Sectional / Observational

Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does CBD work for anxiety?

The evidence is most consistent for anxiety. Across multiple trials, CBD appeared to have anxiolytic (anxiety-reducing) properties. For other conditions, results were inconsistent.

Why are results so inconsistent for other conditions?

Most studies had very small samples (under 40 participants), used widely varying doses (400 mcg to 6,000 mg), and tested different CBD products. This variability makes it difficult to draw clear conclusions.

Is CBD safe?

In the studies reviewed, CBD was generally safe and well-tolerated, even at high doses. However, the authors note that clearer dosing guidelines and increased regulation of CBD products are needed.

Cite This Study

RTHC-04256·https://rethinkthc.com/research/RTHC-04256

APA

Tang, Yuni; Tonkovich, Kolbi L; Rudisill, Toni Marie. (2022). The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.. Pharmaceutical medicine, 36(6), 353-385. https://doi.org/10.1007/s40290-022-00446-8

MLA

Tang, Yuni, et al. "The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.." Pharmaceutical medicine, 2022. https://doi.org/10.1007/s40290-022-00446-8

RethinkTHC

RethinkTHC Research Database. "The Effectiveness and Safety of Cannabidiol in Non-seizure-r..." RTHC-04256. Retrieved from https://rethinkthc.com/research/tang-2022-the-effectiveness-and-safety

Access the Original Study

View on PubMed View via DOI

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.

← Back to Research Database